Automate Your Wheel Strategy on NVO
With Tiblio's Option Bot, you can configure your own wheel strategy including NVO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NVO
- Rev/Share 70.9894
- Book/Share 38.2151
- PB 8.3236
- Debt/Equity 0.5957
- CurrentRatio 0.7761
- ROIC 0.3599
- MktCap 1413913233069.2798
- FreeCF/Share 14.1116
- PFCF 22.5372
- PE 13.6273
- Debt/Assets 0.1976
- DivYield 0.0245
- ROE 0.6695
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | NVO | Citigroup | -- | Neutral | -- | -- | Jan. 27, 2026 |
| Downgrade | NVO | Argus | Buy | Hold | -- | -- | Dec. 8, 2025 |
| Resumed | NVO | Jefferies | -- | Underperform | -- | -- | Oct. 27, 2025 |
| Upgrade | NVO | HSBC Securities | Hold | Buy | -- | -- | Oct. 1, 2025 |
| Downgrade | NVO | Morgan Stanley | Equal Weight | Underweight | -- | $47 | Sept. 29, 2025 |
| Upgrade | NVO | Berenberg | Hold | Buy | -- | -- | Sept. 17, 2025 |
| Upgrade | NVO | Rothschild & Co Redburn | Neutral | Buy | -- | -- | Sept. 16, 2025 |
| Upgrade | NVO | Bernstein | Market Perform | Outperform | -- | -- | Sept. 9, 2025 |
| Upgrade | NVO | BNP Paribas Exane | Underperform | Neutral | -- | $54 | Aug. 13, 2025 |
| Downgrade | NVO | UBS | Buy | Neutral | -- | -- | Aug. 5, 2025 |
News
Eli Lilly's GLP-1 growth is only getting started as Novo Nordisk braces for a decline in 2026
Published: February 04, 2026 by: CNBC
Sentiment: Positive
Both Novo Nordisk and Eli Lilly are grappling with pricing pressure in the U.S., but their 2026 outlooks are diverging sharply. While Novo is bracing for a sales decline, Lilly sees revenue charging ahead thanks to its blockbuster medicines.
Read More
Eli Lilly Soars, Novo Nordisk Plummets On GLP/Obesity Updates - Here's What To Do
Published: February 04, 2026 by: Seeking Alpha
Sentiment: Positive
Eli Lilly and Company defies valuation skeptics, posting 45% revenue growth and 96% EPS growth in 2025, with 2026 guidance projecting $80–83 billion in revenue and $33.5–35 EPS. LLY's manufacturing investments and pipeline strength, especially tirzepatide and retatrutide, position it to outpace Novo Nordisk A/S in the GLP-1/obesity market. NVO faces 2026 revenue and profit declines due to U.S. pricing pressures, patent expiries, and manufacturing disadvantages despite a strong dividend yield.
Read More
In Weight Loss Drug Battle For 2026, Eli Lilly Pulls Ahead Of Novo Nordisk
Published: February 04, 2026 by: Benzinga
Sentiment: Positive
Over the last two days, Novo Nordisk A/S (NYSE: NVO) stock has plunged around 18% after the company issued a softer outlook for fiscal 2026.
Read More
Novo Nordisk Q4: Slumping Due To Weak Guidance
Published: February 04, 2026 by: Seeking Alpha
Sentiment: Negative
Novo Nordisk A/S shares dropped ~20% after issuing weaker-than-expected 2026 guidance despite strong 2025 obesity drug growth. NVO's 2025 revenue rose 10% at constant currency rates, but margin compression and higher costs left net profit flat; the obesity franchise grew 31%. 2026 guidance forecasts ~9% constant currency revenue and profit decline, driven by U.S. drug pricing pressures and patent expirations.
Read More
Novo to launch Ozempic pill for diabetes in second quarter of this year
Published: February 04, 2026 by: Reuters
Sentiment: Positive
Novo Nordisk said on Wednesday it will launch some doses of its oral semaglutide for diabetes under the brand name Ozempic pill in the second quarter of this year.
Read More
Novo Nordisk: My Certainties Swept Away By A Quarterly Report (Downgrade)
Published: February 04, 2026 by: Seeking Alpha
Sentiment: Negative
Novo Nordisk A/S faces disappointing 2026 guidance, projecting a 5–13% revenue and operating profit decline despite Wegovy pill adoption. Margin pressure arises as the oral Wegovy pill is costlier to produce and priced lower than injectables, compressing profitability even amid surging demand. US pricing pressure, currency headwinds, and competition from Eli Lilly compound risks, pushing NVO's FWD price/FCF multiple to 33x amid deteriorating fundamentals.
Read More
Novo Nordisk Stock Sinks on Weak Sales Forecast
Published: February 04, 2026 by: Schaeffers Research
Sentiment: Negative
Novo Nordisk A/S (NYSE:NVO) stock is extending last session's 14.6% slide, down 3.7% to trade at $48.44 at last glance.
Read More
Healthcare ETFs to Watch as Novo Nordisk Tumbles on Poor Sales Outlook
Published: February 04, 2026 by: Zacks Investment Research
Sentiment: Negative
Novo Nordisk slides 15% on a cautious 2026 sales outlook, but buybacks, leadership moves and Wegovy expansion put its ETFs in focus.
Read More
NVO Q4 Earnings & Sales Beat Estimates, Stock Down on Poor 2026 View
Published: February 04, 2026 by: Zacks Investment Research
Sentiment: Positive
Novo Nordisk beats Q4 earnings and sales estimates, but shares slide after management forecasts a 5-13% decline in 2026 sales and operating profit.
Read More
Novo Nordisk risks weight-loss price war as discount pressures deepen
Published: February 04, 2026 by: Reuters
Sentiment: Negative
Danish obesity drug maker Novo Nordisk's new CEO risks being on the losing side of a damaging price war as "unprecedented" price pressure forces it to slash the cost of its blockbuster Wegovy drug in the United States, analysts and investors said.
Read More
Novo Nordisk CEO on 2026 Forecast and GLP-1 Pricing
Published: February 03, 2026 by: Bloomberg Markets and Finance
Sentiment: Neutral
Novo Nordisk CEO Mike Doustdar discusses the company's updated 2026 sales guidance, forecasting a decline of 5 to 13% at constant exchange rates. Doustdar highlights the strong uptake of Novo Nordisk's oral GLP-1 treatment Wegovy, which has reached over 170,000 patients within four weeks of launch.
Read More
Novo Nordisk's stock tumbles as drugmaker lays out case for declining sales in 2026
Published: February 03, 2026 by: Market Watch
Sentiment: Negative
The maker of Ozempic and Wegovy blamed pricing pressures and competition for its downbeat outlook.
Read More
Novo Nordisk warns of 2026 sales decline, shares fall
Published: February 03, 2026 by: Proactive Investors
Sentiment: Negative
Novo Nordisk (NYSE:NVO) shares fell almost 13% on Tuesday as the Danish drugmaker forecast lower sales and profit growth for 2026, citing reduced prices in the United States and loss of exclusivity for its blockbuster GLP-1 drugs Wegovy and Ozempic in several markets. For 2026, Novo Nordisk expects adjusted sales and operating profit to decline between 5% and 13% at constant exchange rates, reversing last year's 10% sales growth.
Read More
Wegovy Maker Novo Nordisk Forecasts Sales Decline in 2026
Published: February 03, 2026 by: WSJ
Sentiment: Negative
The Danish drugmaker said adjusted sales should decline between 5% and 13% at constant exchange rates in 2026, a reversal from last year, when sales grew 10%.
Read More
Novo Nordisk shares tumble 11% after company forecasts sales declines this year
Published: February 03, 2026 by: CNBC
Sentiment: Negative
Novo Nordisk said late Tuesday it sees sales and profit growth declining this year, expecting a U.S. sales hit. Novo's American depositary shares fell 11% on the news.
Read More
Novo Nordisk Posts Better-Than-Expected 2025 Sales. Stock Sinks.
Published: February 03, 2026 by: Barrons
Sentiment: Positive
The Ozempic and Wegovy maker reports full-year sales of 309.1 billion Danish krone, beating analysts' forecasts.
Read More
Novo Nordisk warns of 2026 sales decline
Published: February 03, 2026 by: Reuters
Sentiment: Negative
Wegovy maker Novo Nordisk expects a decline in sales this year, it said on Tuesday as it reported fourth-quarter operating profit slightly above forecasts.
Read More
NVO's CagriSema Outshines Semaglutide in Phase III Diabetes Study
Published: February 03, 2026 by: Zacks Investment Research
Sentiment: Neutral
Novo Nordisk reports that CagriSema beats semaglutide at HbA1c reduction and weight loss in a 68-week phase III diabetes study, with no weight-loss plateau.
Read More
Novo Nordisk releases 2026 sales and operating profit outlook
Published: February 03, 2026 by: GlobeNewsWire
Sentiment: Neutral
In 2025, Novo Nordisk's sales increased by 10% and operating profit increased by 6%, compared to previously issued guidance of 8 to 11% sales growth and
Read More
Citi flags bigger tests ahead after Novo Nordisk diabetes trial success
Published: February 03, 2026 by: Proactive Investors
Sentiment: Neutral
Bank says latest CagriSema results meet expectations, with investor focus shifting to head-to-head data against Eli Lilly's tirzepatide. Novo Nordisk (NYSE:NVO) has reported positive headline results from a late-stage trial of its next-generation diabetes drug CagriSema, but analysts at Citi said the data were largely expected and that more consequential readouts lie ahead.
Read More
What's in Store for These 5 Pharma Bigwigs This Earnings Season?
Published: February 02, 2026 by: Zacks Investment Research
Sentiment: Neutral
As earnings season accelerates, pharma heavyweights LLY, MRK, NVO, BMY and PFE prepare to reveal their Q4 results amid a strong sector start.
Read More
Novo Nordisk says CagriSema outperforms semaglutide in late-stage trial of type-2 diabetes patients
Published: February 02, 2026 by: Reuters
Sentiment: Positive
Novo Nordisk said on Monday its experimental next-generation weight-loss drug CagriSema reduced blood sugar levels and body weight more than semaglutide alone in a late-stage trial of patients with type 2 diabetes.
Read More
Novo Nordisk A/S: CagriSema demonstrated superior HbA1c reduction of 1.91%-points and weight loss of 14.2% in adults with type 2 diabetes in the REIMAGINE 2 trial
Published: February 02, 2026 by: GlobeNewsWire
Sentiment: Neutral
CagriSema achieved superior weight loss of up to 14.2%, where up to 43% of the people achieved ≥15% weight loss and up to 24% achieved ≥20% weight loss1. CagriSema achieved superior HbA1c reduction of up to 1.91%-points1 from a mean HbA1c baseline of 8.2%.
Read More
Novo Nordisk Before Q4 Earnings: How Should Investors Play the Stock?
Published: January 30, 2026 by: Zacks Investment Research
Sentiment: Negative
NVO faces slowing Wegovy and Ozempic sales momentum, pricing pressures and fierce competition ahead of Q4 earnings.
Read More
Novo Nordisk: Momentum Meets Headwinds Before Earnings (Upgrade)
Published: January 30, 2026 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk A/S has first-mover advantage in obesity pills and aggressive U.S. marketing, supported by a robust cash position, strengthen its competitive stance in the thriving GLP-1 market. Consensus revenue growth forecasts appear overly pessimistic given NVO's historical double-digit growth and Q4 seasonal strength. Despite positives, technical setup, high valuation (PEG 3.3 vs. 1.8 sector median), and potential profit-taking temper enthusiasm make NVO a Hold.
Read More
New play in Denmark charts Novo Nordisk's weight loss boom
Published: January 30, 2026 by: Reuters
Sentiment: Neutral
A play examining the meteoric rise of Danish weight-loss drug giant Novo Nordisk will premiere on Saturday at a theatre outside Copenhagen.
Read More
Novo Nordisk: Investors May Be In For An Earnings Surprise
Published: January 28, 2026 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk could be poised for a temporary negative sentiment swing as Q4 earnings may include highly conservative 2026 guidance despite strong oral Wegovy prescription momentum. Recent news - such as oral Wegovy's rapid uptake, Lilly's FDA delays, UK approval, and an Amazon partnership have all fueled a 20% rally, but upside appears limited pre-earnings. Management is likely to under promise on 2026 guidance to set up a runway for consistent beats and positive revisions as oral Wegovy's impact materializes, in my view.
Read More
Novo Nordisk vs. Viking: Which Obesity Drug Stock is the Safer Bet?
Published: January 27, 2026 by: Zacks Investment Research
Sentiment: Neutral
NVO and VKTX face rising competition and setbacks as investors weigh scale, pipelines and execution risks in the crowded obesity drug race.
Read More
Novo Nordisk: The Q4 Setup Favors Another Beat (Earnings Preview)
Published: January 26, 2026 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk A/S's restructuring costs are front-loaded in Q3, with DKK 1 billion in savings accruing to Q4 earnings, setting up a potential beat on low expectations. The FDA-approved Wegovy oral pill launched in January 2026 with 18,000+ prescriptions in its debut week, expanding the addressable market to approximately 85 million Americans. Catalent fill-finish site integration is expected to double U.S. supply chain capacity by mid-2026, supporting margin expansion and reducing manufacturing bottlenecks going forward.
Read More
How Will Ozempic and Wegovy Sales Aid NVO's Upcoming Q4 Results?
Published: January 26, 2026 by: Zacks Investment Research
Sentiment: Negative
Novo Nordisk's Q4 results hinge on Ozempic and Wegovy sales as demand growth slows amid guidance cuts due to intense rivalry and compounded drug headwinds.
Read More
About Novo Nordisk A/S (NVO)
- IPO Date 1981-04-30
- Website https://www.novonordisk.com
- Industry Drug Manufacturers - General
- CEO Maziar Mike Doustdar
- Employees 77406